Avita Medical's (RCEL) "Buy" Rating Reaffirmed at D. Boral Capital

Key Points

• Avita Medical's stock received a "buy" rating with a target price of $14.00 from D. Boral Capital, indicating a potential upside of 207.02% from its current price.
• Despite this positive outlook, Avita Medical has recently faced downgrades from other analysts, including a "sell" rating from BTIG Research with a $3.00 target price.
• The company reported a loss of ($0.38) earnings per share for the last quarter, missing estimates, and has a market cap of $121.39 million.

Avita Medical (NASDAQ:RCEL - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $14.00 target price on the stock. D. Boral Capital's price target would suggest a potential upside of 207.02% from the stock's current price.

RCEL has been the topic of a number of other reports. BTIG Research downgraded shares of Avita Medical from a "neutral" rating to a "sell" rating and set a $3.00 target price on the stock. in a research report on Friday, August 8th. Lake Street Capital decreased their price target on shares of Avita Medical from $14.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Finally, Wall Street Zen cut shares of Avita Medical from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $11.60.

Avita Medical Stock Up 4.1%

RCEL opened at $4.56 on Monday. The firm's 50-day simple moving average is $5.10 and its 200-day simple moving average is $6.70. The company has a debt-to-equity ratio of 9.39, a quick ratio of 0.46 and a current ratio of 0.58. Avita Medical has a twelve month low of $3.60 and a twelve month high of $14.16. The firm has a market cap of $121.39 million, a price-to-earnings ratio of -2.31 and a beta of 1.58.

Avita Medical (NASDAQ:RCEL - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.12). Avita Medical had a negative return on equity of 632.62% and a negative net margin of 68.87%.The firm had revenue of $18.42 million during the quarter, compared to the consensus estimate of $34.27 million. Avita Medical has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Avita Medical will post -0.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Robert Mcnamara bought 10,000 shares of the firm's stock in a transaction on Thursday, August 28th. The stock was acquired at an average price of $4.50 per share, with a total value of $45,000.00. Following the transaction, the director owned 86,771 shares of the company's stock, valued at $390,469.50. This trade represents a 13.03% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have purchased 24,000 shares of company stock worth $113,660. Corporate insiders own 2.80% of the company's stock.

Hedge Funds Weigh In On Avita Medical

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new position in shares of Avita Medical during the 4th quarter worth approximately $38,000. CWM LLC boosted its holdings in shares of Avita Medical by 1,099.5% during the 1st quarter. CWM LLC now owns 4,918 shares of the company's stock worth $40,000 after buying an additional 4,508 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Avita Medical by 688.9% during the 1st quarter. GAMMA Investing LLC now owns 6,374 shares of the company's stock worth $52,000 after buying an additional 5,566 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Avita Medical during the 1st quarter worth approximately $53,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Avita Medical during the 2nd quarter worth approximately $58,000. 27.66% of the stock is currently owned by institutional investors.

Avita Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.